CD21S antigen expression in tumour cells of diffuse large B‐cell lymphomas is an independent prognostic factor indicating better overall survival
CD21S antigen expression in tumour cells of diffuse large B‐cell lymphomas is an independent prognostic factor indicating better overall survival
复制标题
DOI：
10.1111/j.1365-2141.2004.04900.x
复制
发表时间：
2004-04
影响因子：
6.5
通讯作者：
Shoko Ogawa;M. Yamaguchi;K. Oka;M. Taniguchi;Motohiro Ito;K. Nishii;K. Nakase;T. Ohno;K. Kita;Tohru Kobayashi;H. Shiku
中科院分区：
文献类型：
--
作者：
Shoko Ogawa;M. Yamaguchi;K. Oka;M. Taniguchi;Motohiro Ito;K. Nishii;K. Nakase;T. Ohno;K. Kita;Tohru Kobayashi;H. Shiku
为了评价弥漫性大B细胞淋巴瘤（DLBCL）肿瘤细胞CD 21 S表达的临床意义，我们比较了它们的临床特征、免疫表型、治疗反应和与CD 21 S表达相关的结局。1987年至1999年，我们用免疫组化方法检测了240例DLBCL的冰冻切片中CD 21 S的表达。87例（36%）肿瘤细胞表达CD 21 S。CD 21 S + DLBCL病例的中位年龄为65岁（范围：17-84岁），男女比例为42：45，他们表现出以下临床特征：东部肿瘤协作组评分>1的占14%，乳酸脱氢酶高于正常水平的占38%，结节部位>1的占14%，诊断时III/IV期疾病的占29%，B症状的占17%，高/高-中等国际预后指数（IPI）为23%。它们还显示出比CD 21 S-DLBCL更好的总生存率（P = 0.00001，对数秩检验）和更好的完全缓解率（P = 0.00004，卡方检验）。此外，对于IPI的低/低-中等和高/高-中等风险类别，CD 21 S + DLBCL的生存率均优于CD 21 S − DLBCL（分别为P = 0.045和P = 0.0016）。多变量分析表明，与5个IPI因素相比，CD 21 S表达是生存的独立因素。这些发现表明DLBCL肿瘤细胞的CD 21 S表达是一个有用的生存预后因素。
To evaluate the clinical significance of CD21S expression of diffuse large B‐cell lymphoma (DLBCL) tumour cells, we compared their clinical features, immunophenotype, response to therapy and outcome in relation to CD21S expression. Between 1987 and 1999, frozen sections from 240 DLBCL cases were examined for CD21S expression by immunohistochemical methods. CD21S expression was detected on the tumour cells of 87 (36%) cases. The median age of the CD21S+ DLBCL cases was 65 years (range: 17–84 years), the male–female ratio was 42:45, and they showed the following clinical features: Eastern Cooperative Oncology Group score >1 in 14%, lactate dehydrogenase greater than normal levels in 38%, extranodal sites >1 in 14%, stages III/IV disease at diagnosis in 29%, B symptoms in 17%, and a high/high–intermediate International Prognostic Index (IPI) in 23%. They also showed a better overall survival (P = 0·00001, log‐rank test) and a better complete remission rate (P = 0·00004, chi‐square test) than CD21S− DLBCL. Moreover, CD21S+ DLBCL showed a better survival than CD21S− DLBCL for both low/low–intermediate and high/high–intermediate risk categories of IPI (P = 0·045 and P = 0·0016 respectively). Multivariate analysis identified CD21S expression as an independent factor for survival when compared with the five IPI factors. These findings indicate that CD21S expression of DLBCL tumour cells is a useful prognostic factor for survival.